Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO6958688 |
Synonyms | |
Therapy Description |
RO6958688 (cibisatamab) is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (PMID: 30982469). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO6958688 | RG7802|Cibisatamab|CEA-TCB|RO-6958688 | CD3 Antibody 99 | RO6958688 (cibisatamab) is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (PMID: 30982469). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|